Key Drivers
- Strong cash flow
- Thin profitability
- Rich valuation
AIAI Summary
Takeda has shifted from a defensive pharma name to a catalyst-driven turnaround: strong free cash flow and several late-stage pipeline wins could re-rate the stock, but only if management can convert them fast enough to offset legacy revenue erosion, restructuring costs, and FX headwinds.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong cash flow
- •Thin profitability
- •Rich valuation
TAK generates strong cash flow and has improving near-term margins, but its low annual profitability, stretched earnings valuation, and balance-sheet/intangible asset risks make the stock look more cautious than compelling.
Price Behavior
Key Price Behavior Insights:
- •Downtrend intact
- •Mid-$16 support
- •Resistance capped
TAK has been trending lower last month, finding support in the mid-$16s but still facing resistance near $16.70 and $17.00, so the setup remains cautious until it breaks higher.
Brief rebound after dipping to $16.30 suggests buyers are defending the mid-$16 area
Sentiment & News
Key News Insights:
- •Cost cuts
- •Pipeline progress
- •Legacy pressure
Takeda's outlook is mixed: legacy-product revenue pressure and planned 4,500 job cuts weigh on near-term results, but positive TAK-881 trial data and a three-launch pipeline support longer-term growth.
Takeda shares may stay range-bound in the near term as restructuring and pipeline gains offset revenue drag from VYVANSE exclusivity loss
Similar Companies in Healthcare
Other companies in the same sector with AI ratings